Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions (2022)
Attributed to:
University of Oxford – Confidence in Concept 2019
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Conference/Paper/Proceeding/Abstract
Volume: 22
Parent Publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN: 2152-2650